| Name | NVP-BAW2881 |
| Description | NVP-BAW2881 (BAW2881) is a potent and selective VEGFR (vascular endothelial growth factor receptor tyrosine kinase) inhibitor with efficacy in inhibiting chronic and acute skin inflammation. |
| Cell Research | HUVECs or LECs (1.2×103) were seeded into fibronectin-coated 96-well plates. After 24 hours, the cells were transferred into LEC medium containing 2% fetal bovine serum and incubated for an additional 24 hours. Cells(eight wells/condition) were incubated with medium alone(control), 20 ng/ml VEGF-A, or a combination of 20 ng/ml VEGF-A and 1 nmol/L to 1 mol/L NVP-BAW2881. Proliferation was also assayed in LECs incubated with 500 ng/ml VEGF-C. The dimethyl sulfoxide concentration was adjusted to 0.1% in all wells. After 72 hours, cells were incubated with 5-methylumbelliferylheptanoate for subsequent fluorescent quantification of viable cells, using a SpectraMax Gemini electron microscope. (Only for Reference) |
| In vitro | In vitro experiments demonstrated that NVP-BAW2881 was able to inhibit the proliferation, migration, and tubulogenesis of human lymphatic endothelial cells and umbilical vein endothelial cells. |
| In vivo | In vitro experiments demonstrated that NVP-BAW2881 was able to inhibit the proliferation, migration, and tubulogenesis of human lymphatic endothelial cells and umbilical vein endothelial cells. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.71 mM), Sonication is recommended.
DMSO : 78 mg/mL (183.8 mM), Sonication is recommended.
Ethanol : 16 mg/mL (37.7 mM), Sonication is recommended.
|
| Keywords | VEGFR | Vascular endothelial growth factor receptor | NVP-BAW-2881 | NVP-BAW2881 | NVPBAW2881 | NVP-BAW 2881 | NVP BAW2881 | Inhibitor | inhibit | hVEGFR2 | C-Raf-1 | c-Abl | B-Raf (V599E) | BcrAbl | BAW-2881 | BAW 2881 |
| Inhibitors Related | Ribociclib | Sorafenib | Dasatinib | glycine | Nintedanib esylate | Regorafenib | Dabrafenib | Chloramphenicol | Thymoquinone | Lenvatinib | Pazopanib | Albendazole |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Hematonosis Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | MAPK Inhibitor Library |
United States
